Dear Well-wishers, I am pleased to meet you through this March 2023 edition of Oviya MedSafe‘s newsletter (the 124th in the series since April 2012) in which I intend to outline some practical challenges faced by fast-growing multinational pharma/biotech/healthcare companies when they begin to constitute an integrated global Pharmacovigilance system aimed at attaining total regulatory […]